Erodium Plant Extract Composition for Anti-Inflammatory Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective anti-inflammatory and antioxidant agents derived from Erodium crassifolium L'Her plant extracts to treat inflammatory and oxidative stress-related disorders.
Innovation Solution
The development of a composition comprising epigallocatechin, mannofuranose, α-D-xylopyranose, gallic acid, palmitic acid, stearic acid, trans-catechin, cis-catechin, and an acceptable carrier, derived from polar extracts of Erodium plant tubers, which exhibits significant in vitro anti-inflammatory activity by reducing interleukin-8 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional Erodium plant extracts are used for anti-inflammatory treatment, then broad medicinal value is achieved, but specific efficacy against inflammatory markers is insufficient
Solution Approach 1:
The patent segments the complex Erodium extract into specific isolated compounds (epigallocatechin, mannofuranose, α-D-xylopyranose, gallic acid, palmitic acid, stearic acid, trans-catechin, cis-catechin) with defined concentration ranges. This segmentation allows for standardized dosing and predictable anti-inflammatory efficacy while reducing the uncertainty associated with variable natural extracts.
Solution Approach 2:
The patent specifies precise parameter ranges for each compound concentration (e.g., epigallocatechin at 35-50% w/w, mannofuranose at 15-22% w/w) to optimize anti-inflammatory activity. By controlling these compositional parameters, the invention achieves reliable efficacy against inflammatory markers while maintaining manufacturability through standardized formulation.
2Manufacturing precision
If polar extracts of Erodium tubers are developed into standardized composition, then manufacturing precision is improved, but extraction process complexity increases
Solution Approach 1:
The patent defines specific parameter ranges for the final composition (concentrations of eight specific compounds) that can be achieved through polar extraction methods. By establishing these target parameters, the invention enables quality control and standardization while the extraction process complexity is managed through focused isolation of specific compounds rather than whole-plant extraction.
Solution Approach 2:
The patent applies extraction methodology to isolate specific active compounds (epigallocatechin, mannofuranose, α-D-xylopyranose, gallic acid, palmitic acid, stearic acid, trans-catechin, cis-catechin) from the Erodium tuber matrix. This selective extraction achieves manufacturing precision by obtaining pure compounds in defined concentrations while avoiding the complexity of processing entire plant material.
3Reliability
If multiple active compounds are combined in specific ratios, then therapeutic effectiveness is improved, but formulation complexity increases
Solution Approach 1:
The patent creates a composite formulation containing eight specific compounds in defined concentration ranges (e.g., epigallocatechin 35-50%, mannofuranose 15-22%, α-D-xylopyranose 1.5-3.5%, gallic acid 3-7%, palmitic acid 4-8%, stearic acid 0.5-3.5%, trans-catechin 8-15%, cis-catechin 7-16%). This composite approach leverages synergistic effects of multiple compounds for enhanced therapeutic effectiveness while the specific ratio definitions enable standardized manufacturing.
Solution Approach 2:
The patent establishes specific concentration parameter ranges for each compound in the formulation to optimize therapeutic effectiveness. By controlling these parameters within defined ranges rather than using fixed ratios, the invention achieves reliable efficacy while allowing for manufacturing flexibility and natural variation in source material.
Data Source
AI summary
The present invention is directed to a composition consisting essentially of epigallocatechin, mannofuranose, α-D-xylopyranose, gallic acid, palmitic acid, stearic acid, trans-catechin, cis-catechin, and an acceptable carrier, and a method of using same, such as for treating an inflammatory disease.